84658-09-3

Basic information

• Product Name: Benzene, 1-(chloromethyl)-4-methoxy-2-methyl-
• CAS NO: 84658-09-3
• Molecular Formula: C9H11ClO
• Molecular Weight: 170.639
• Mol File: 84658-09-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(chloromethyl)-4-methoxy-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(chloromethyl)-4-methoxy-2-methyl-(84658-09-3)
• EPA Substance Registry System: Benzene, 1-(chloromethyl)-4-methoxy-2-methyl-(84658-09-3)

Safety Data

• Hazardous Substances Data: 84658-09-3(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 100-84-5 1-methoxy-3-methyl-benzene 
• 35598-05-1 methyl 4-methoxy-2-methylbenzoate 
• 578-39-2 4-hydroxy-2-methylbenzoic acid 
• 52289-54-0 4-methoxysalicylaldehyde 
• 52289-55-1 (4-methoxy-2-methylphenyl)methanol 

Downstream Products

• 52289-55-1 (4-methoxy-2-methylphenyl)methanol 
• 262298-02-2 2-(4-methoxy-2-methylphenyl)acetonitrile 
• 6245-57-4 4-methoxy-2-methylbenzoic acid 
• 851376-97-1 3-(4-chloro-phenyl)-2-(4-methoxy-2-methyl-benzyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene-6-carboxylic acid tert-butyl ester 
• 851376-96-0 3-(4-chloro-phenyl)-1-(4-methoxy-2-methyl-benzyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene-6-carboxylic acid tert-butyl ester 
• 4685-47-6 3,4-dimethylanisole 

Relevant articles and documents

On the Necessity of Nucleobase Protection for 2-Thiouracil for Fmoc-Based Pseudo-Complementary Peptide Nucleic Acid Oligomer Synthesis

A selection of benzyl-based protecting groups for thiouracil (SU) for the synthesis of pseudo-complementary peptide nucleic acid (PNA) has been evaluated. The 4-methoxybenzyl-protecting group that has found use for SU during Boc-based oligomerization is also suitable for Fmoc-based oligomerization. Furthermore, it is demonstrated that SU protection is unnecessary for the successful synthesis of thiouracil-containing PNA. The new 2-thiothymine (ST) PNA monomer has also been prepared and incorporated into an oligomer and its binding to complementary PNA evaluated.

TETRAHYDROISOQUINOLINE COMPOUND

The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.